170 related articles for article (PubMed ID: 37998793)
21. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Malaysia: Results from the ATLAS Programme, 2013 to 2019.
Tuan Soh TS; Salvinder S; Chen VSY
Med J Malaysia; 2022 Mar; 77(2):174-184. PubMed ID: 35338624
[TBL] [Abstract][Full Text] [Related]
22. Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacteriaceae isolates in Southwest China: A single-centre study.
Wei J; Zou C; Wang D; Huang A; Niu S
J Glob Antimicrob Resist; 2020 Sep; 22():448-451. PubMed ID: 32387260
[TBL] [Abstract][Full Text] [Related]
23. Ceftazidime/Avibactam and Other Commonly Used Antibiotics Activity Against Enterobacterales and
Zalas-Więcek P; Prażyńska M; Pojnar Ł; Pałka A; Żabicka D; Orczykowska-Kotyna M; Polak A; Możejko-Pastewka B; Głowacka EA; Pieniążek I; Pawlik M; Grys M; Bogiel M
Infect Drug Resist; 2022; 15():1289-1304. PubMed ID: 35370409
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
Ko WC; Stone GG
Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
[TBL] [Abstract][Full Text] [Related]
25. In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant
Kim T; Lee SC; Bae M; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Chong YP
Antibiotics (Basel); 2020 Dec; 9(12):. PubMed ID: 33334045
[TBL] [Abstract][Full Text] [Related]
26. In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Emeraud C; Bernabeu S; Dortet L
Antibiotics (Basel); 2023 Sep; 12(10):. PubMed ID: 37887194
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019.
Karlowsky JA; Kazmierczak KM; Valente MLNF; Luengas EL; Baudrit M; Quintana A; Irani P; Stone GG; Sahm DF
Braz J Infect Dis; 2021; 25(6):101647. PubMed ID: 34774471
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015‒2020.
Wise MG; Karlowsky JA; Lemos-Luengas EV; Valdez RR; Sahm DF
Braz J Infect Dis; 2023; 27(3):102759. PubMed ID: 36977498
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
Le Terrier C; Nordmann P; Poirel L
J Antimicrob Chemother; 2022 Dec; 78(1):101-107. PubMed ID: 36308322
[TBL] [Abstract][Full Text] [Related]
31. Ceftazidime-avibactam and comparators against Pseudomonas aeruginosa isolates collected globally and in each geographical region between 2017-2020.
Kiratisin P; Kempf M; Stone G; Utt E
J Glob Antimicrob Resist; 2023 Sep; 34():113-118. PubMed ID: 37422001
[TBL] [Abstract][Full Text] [Related]
32. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
Lin Q; Zou H; Chen X; Wu M; Ma D; Yu H; Niu S; Huang S
BMC Microbiol; 2021 Feb; 21(1):60. PubMed ID: 33618662
[TBL] [Abstract][Full Text] [Related]
33. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
[TBL] [Abstract][Full Text] [Related]
34.
Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
[TBL] [Abstract][Full Text] [Related]
35. Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21).
Sader HS; Castanheira M; Kimbrough JH; Kantro V; Mendes RE
JAC Antimicrob Resist; 2023 Apr; 5(2):dlad032. PubMed ID: 36968952
[TBL] [Abstract][Full Text] [Related]
36. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
[TBL] [Abstract][Full Text] [Related]
37. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL
Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408
[TBL] [Abstract][Full Text] [Related]
38. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing
Bhatnagar A; Boyd S; Sabour S; Bodnar J; Nazarian E; Peinovich N; Wagner C; Craft B; Snippes Vagnone P; Simpson J; Stone VN; Therrien M; Bateman A; Lower D; Huang JY; Gumbis S; Lonsway D; Lutgring JD; Karlsson M; Brown AC
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0048621. PubMed ID: 34060895
[TBL] [Abstract][Full Text] [Related]
39.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
40. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]